Heart Failure after Ischemic Stroke or TIA in Insulin-Resistant Patients without Diabetes Treated with Pioglitazone

BACKGROUND: The Insulin Resistance Intervention after Stroke (IRIS) trial demonstrated that pioglitazone reduced risk for both cardiovascular events and diabetes in insulin resistant patients. However, concern remains that pioglitazone may increase risk for heart failure (HF) in susceptible individu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Circulation
Autores principales: Young, Lawrence H., Viscoli, Catherine M., Schwartz, Gregory G., Inzucchi, Silvio E., Curtis, Jeptha P., Gorman, Mark J., Furie, Karen L., Conwit, Robin, Spatz, Erica, Lovejoy, Anne, Abbott, J. Dawn, Jacoby, Daniel L., Kolansky, Daniel M., Ling, Frederick S., Pfau, Steven E., Kernan, Walter N.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6202153/
https://ncbi.nlm.nih.gov/pubmed/29934374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.118.034763
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares